A Single Institutional Experience Using Romiplostim to Treat Therapy-Related Thrombocytopenia in Pediatric Solid
Melanie D Degliuomini1, Katherine Armstrong1, Michael Curry2
1Department of Pediatrics, Hackensack University Medical Center, Hackensack, New Jersey, USA.
None:
Chemotherapy-induced thrombocytopenia (CIT) is a common toxicity in patients with cancer, leading to chemotherapy dose reductions and increased platelet transfusions. Although there are well-documented data using thrombopoietin receptor agonists (TPO-RA) in both adult CIT and pediatric immune thrombocytopenia, there is a paucity of data in pediatric CIT. This is a single institutional, retrospective study evaluating the use and safety of romiplostim in pediatric patients with solid tumors undergoing cancer treatment. Romiplostim was well tolerated and appeared to provide clinical benefit. This report advocates for further research using TPO-RA in pediatric patients being treated for cancer.
Related Concept Videos
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Treatment Resistant Cancers
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Tumor Immunotherapy
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents


